株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ベーチェット病治療薬の世界市場:2019年~2023年

Behcet's Disease Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 909630
出版日 ページ情報 英文 150 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
ベーチェット病治療薬の世界市場:2019年~2023年 Behcet's Disease Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023
出版日: 2019年08月28日 ページ情報: 英文 150 Pages
概要

世界のベーチェット病治療薬市場は、医薬品の適応外大量使用、特別薬の指定、希少疾患に対する研究資金の増加などが成長促進要因となり、予測期間中に6%以上のCAGRで拡大する見込みです。ただし、診断の難しさ、小分子ベースの薬物の副作用、特発性疾患の性質などの要因が、予測期間中のベーチェット病治療薬産業の成長を妨げる可能性があります。

当レポートでは、世界のベーチェット病治療薬市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:製品別

  • 市場セグメンテーション:製品別
  • 比較:製品市場規模および予測(2018年~2023年)
  • 小分子
  • 生物製剤
  • 市場機会:製品別

第7章 顧客情勢

第8章 地域別景観

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競争シナリオ

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • AbbVie Inc.
  • Amgen Inc.
  • Celgene Corp.
  • エーザイ
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • 武田薬品工業

第14章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第15章 TECHNAVIOについて

目次
Product Code: IRTNTR31936

About this market

Technavio's Behcet's disease therapeutics market analysis considers sales from both small molecules and biologics. Our analysis also considers the sales of Behcet's disease therapeutics in Asia, Europe, North America, and ROW. In 2018, the small molecules segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as cost-effectiveness and strong penetration will play a significant role in the small molecules segment to maintain its market position. Also, our global Behcet's disease therapeutics market report looks at factors such as heavy use of off-label drugs, special drug designations, and increasing research funding for rare diseases. However, difficulty in diagnosis, adverse effects of small molecule-based drugs, and idiopathic nature of the disease may hamper the growth of the Behcet's disease therapeutics industry over the forecast period.

Overview

Increasing research funding for rare diseases

Currently, global Behcet's disease therapeutics market has only two approved drugs for the treatment of the condition. Although the condition is rare, its increasing prevalence is leading to the intense R&D novel therapies by vendors and research institutes for the development of treatment for Behcet's disease. These vendors and institutes rely on grants from organizations that provide research funding. These organizations aim to improve the quality of life of patients' vasculitis and associated diseases and increases awareness about rare diseases among public and medical practitioners. This will lead to the expansion of the global Behcet's disease therapeutics market at a CAGR of over 6% during the forecast period.

The advent of novel therapies

Behcet's disease is also considered to be associated with genetic mutations and autoimmune disorders, for which the market has a huge unmet need. The reason for the growing preference for a novel therapy for the treatment of life-threatening disorders is its curative nature. The huge unmet need has attracted various pharmaceutical companies and academic institutions to invest substantially in the R&D of novel therapies for the treatment of Behcet's disease. Factors such as recent advances in the research of these novel therapies are attracting the companies to start the research on gene therapy for Behcet's disease. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global Behcet's disease therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global Behcet's disease therapeutics market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Behcet's disease therapeutics manufacturers. These include AbbVie Inc., Amgen Inc., Celgene Corp., Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd.

Also, Behcet's disease therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Small molecules - Market size and forecast 2018-2023
  • Biologics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Amgen Inc.
  • Celgene Corp.
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Small molecules - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Small molecules - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Biologics - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Drug designations
  • Exhibit 43: Side effects of small molecule-based drugs used for treatment of Behcet's disease
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: Vendor landscape
  • Exhibit 46: Landscape disruption
  • Exhibit 47: Vendors covered
  • Exhibit 48: Vendor classification
  • Exhibit 49: Market positioning of vendors
  • Exhibit 50: AbbVie Inc. - Vendor overview
  • Exhibit 51: AbbVie Inc. - Business segments
  • Exhibit 52: AbbVie Inc. - Organizational developments
  • Exhibit 53: AbbVie Inc. - Geographic focus
  • Exhibit 54: AbbVie Inc. - Key offerings
  • Exhibit 55: AbbVie Inc. - Key customers
  • Exhibit 56: Amgen Inc. - Vendor overview
  • Exhibit 57: Amgen Inc. - Product segments
  • Exhibit 58: Amgen Inc. - Organizational developments
  • Exhibit 59: Amgen Inc. - Geographic focus
  • Exhibit 60: Amgen Inc. - Key offerings
  • Exhibit 61: Amgen Inc. - Key customers
  • Exhibit 62: Celgene Corp. - Vendor overview
  • Exhibit 63: Celgene Corp. - Business segments
  • Exhibit 64: Celgene Corp. - Organizational developments
  • Exhibit 65: Celgene Corp. - Geographic focus
  • Exhibit 66: Celgene Corp. - Key offerings
  • Exhibit 67: Celgene Corp. - Key customers
  • Exhibit 68: Eisai Co. Ltd. - Vendor overview
  • Exhibit 69: Eisai Co. Ltd. - Business segments
  • Exhibit 70: Eisai Co. Ltd. - Organizational developments
  • Exhibit 71: Eisai Co. Ltd. - Geographic focus
  • Exhibit 72: Eisai Co. Ltd. - Segment focus
  • Exhibit 73: Eisai Co. Ltd. - Key offerings
  • Exhibit 74: Eisai Co. Ltd. - Key customers
  • Exhibit 75: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 76: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 77: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 78: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 79: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 80: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 81: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 82: Johnson & Johnson Services, Inc. - Vendor overview
  • Exhibit 83: Johnson & Johnson Services, Inc. - Business segments
  • Exhibit 84: Johnson & Johnson Services, Inc. - Organizational developments
  • Exhibit 85: Johnson & Johnson Services, Inc. - Geographic focus
  • Exhibit 86: Johnson & Johnson Services, Inc. - Segment focus
  • Exhibit 87: Johnson & Johnson Services, Inc. - Key offerings
  • Exhibit 88: Johnson & Johnson Services, Inc. - Key customers
  • Exhibit 89: Mylan NV - Vendor overview
  • Exhibit 90: Mylan NV - Product segments
  • Exhibit 91: Mylan NV - Organizational developments
  • Exhibit 92: Mylan NV - Geographic focus
  • Exhibit 93: Mylan NV - Segment focus
  • Exhibit 94: Mylan NV - Key offerings
  • Exhibit 95: Mylan NV - Key customers
  • Exhibit 96: Novartis AG - Vendor overview
  • Exhibit 97: Novartis AG - Business segments
  • Exhibit 98: Novartis AG - Organizational developments
  • Exhibit 99: Novartis AG - Geographic focus
  • Exhibit 100: Novartis AG - Segment focus
  • Exhibit 101: Novartis AG - Key offerings
  • Exhibit 102: Novartis AG - Key customers
  • Exhibit 103: Pfizer Inc. - Vendor overview
  • Exhibit 104: Pfizer Inc. - Business segments
  • Exhibit 105: Pfizer Inc. - Organizational developments
  • Exhibit 106: Pfizer Inc. - Geographic focus
  • Exhibit 107: Pfizer Inc. - Segment focus
  • Exhibit 108: Pfizer Inc. - Key offerings
  • Exhibit 109: Pfizer Inc. - Key customers
  • Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Vendor overview
  • Exhibit 111: Takeda Pharmaceutical Co. Ltd. - Business segments
  • Exhibit 112: Takeda Pharmaceutical Co. Ltd. - Organizational developments
  • Exhibit 113: Takeda Pharmaceutical Co. Ltd. - Geographic focus
  • Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • Exhibit 115: Takeda Pharmaceutical Co. Ltd. - Key customers
  • Exhibit 116: Validation techniques employed for market sizing
  • Exhibit 117: Definition of market positioning of vendors
Back to Top